Healthcare provider profile · identity verified

Nohemy Morones

Family Practice · LOS ANGELES, CA · NPI 1689100612

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	309	126
Amlodipine Besylate	Amlodipine Besylate	166	71
Lisinopril	Lisinopril	163	69
Levothyroxine Sodium	Levothyroxine Sodium	162	59
Losartan Potassium	Losartan Potassium	161	66
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	123	56
Alendronate Sodium	Alendronate Sodium	112	52
Rosuvastatin Calcium	Rosuvastatin Calcium	111	55
Albuterol Sulfate Hfa	Albuterol Sulfate	105	49
Pantoprazole Sodium	Pantoprazole Sodium	104	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	99	38
Metformin Hcl	Metformin Hcl	90	41
Metformin Hcl Er	Metformin Hcl	87	39
Hydrochlorothiazide	Hydrochlorothiazide	86	37
Omeprazole	Omeprazole	83	42
Meloxicam	Meloxicam	80	35
Glipizide	Glipizide	67	29
Simvastatin	Simvastatin	67	24
Ibuprofen	Ibuprofen	64	23
Trazodone Hcl	Trazodone Hcl	56	25
Gabapentin	Gabapentin	54	28
Ozempic	Semaglutide	45	19
Metoprolol Succinate	Metoprolol Succinate	44	15
Potassium Chloride	Potassium Chloride	39	23
Furosemide	Furosemide	37	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Pregabalin	Pregabalin	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	35	20
Tramadol Hcl	Tramadol Hcl	35	21
Prednisone	Prednisone	33	28
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	32	15
Atenolol	Atenolol	31	15
Metoprolol Tartrate	Metoprolol Tartrate	31	15
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	29	28
Terazosin Hcl	Terazosin Hcl	29	12
Pradaxa	Dabigatran Etexilate Mesylate	28	12
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	23	11
Clopidogrel	Clopidogrel Bisulfate	22	12
Finasteride	Finasteride	22	suppressed
Jardiance	Empagliflozin	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	18
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Azithromycin	Azithromycin	18	18
Estradiol	Estradiol	18	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	18
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Spironolactone	Spironolactone	17	suppressed
Topiramate	Topiramate	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Naltrexone Hcl	Naltrexone Hcl	16	suppressed
Ondansetron Odt	Ondansetron	16	12
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Famotidine	Famotidine	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Alvesco	Ciclesonide	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	13	suppressed
Nystatin	Nystatin	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Trospium Chloride	Trospium Chloride	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Primidone	Primidone	12	suppressed
Sertraline Hcl	Sertraline Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error